Denali Therapeutics Gets $200m from Royalty Deal Denali received $200m upfront under a royalty agreement (SEC filing, Mar 31, 2026), a material liquidity event that changes future revenue rights and valuation dynamics.

Denali Therapeutics Gets $200m from Royalty Deal: Denali received $200m upfront under a royalty agreement (SEC filing, Mar 31, 2026), a material liquidity event that changes future revenue rights and… 👈 Read full analysis #DenaliTherapeutics #RoyaltyDeal #Biotechnology #Investment #PharmaNews